Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy

AKINCI B., DEMİR T., Saygili S., Yener S., ALACACIOĞLU İ., Saygili F., ...Daha Fazla

DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.81, sa.1, ss.93-96, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 81 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/j.diabres.2008.03.003
  • Dergi Adı: DIABETES RESEARCH AND CLINICAL PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.93-96
  • Anahtar Kelimeler: diabetes, pregnancy, fibrinolysis, TAFI, PAI-1, TAFI ANTIGEN, INSULIN-RESISTANCE, MELLITUS, ASSOCIATION, DYSFUNCTION, PAI-1, STATE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Pregnancy is a prothrombotic condition with increased levels of several circulating coagulation factors. Decreased fibrinolytic activity has been shown in gestational diabetes. Gestational diabetes has been found to be associated with higher plasma plasminogen activator inhibitor-1 (PAI-1) antigen levels than normal pregnancy. The aim of the present study is to investigate the effect of gestational diabetes on plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels.